uniQure N.V.

uniQure N.V. develops treatments for rare and devastating diseases. Its product HEMGENIX completed Phase III trials for hemophilia B treatment. Gene therapy AMT-130 is in Phase I/II for Huntingtons disease. Other pipeline products include: AMT-162 (superoxide dismutase 1-amyotrophic lateral sclerosis), AMT-260 (temporal lobe epilepsy), AMT-191 (Fabry disease), AMT-161 (amyotrophic lateral sclerosis caused by mutations), AMT-240 (autosomal dominant Alzheimers disease), and AMT-210 (Parkinsons disease). The company was founded in 1998 and is headquartered in Amsterdam.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

15.9 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	0.6